Reply to: "mRECIST for systemic therapies: More evidence is required before recommendations could be made"

Affiliations

¹ Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain.
² Department of Interventional Radiology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
³ Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Ichan School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address: jmllovet@clinic.cat.

Comment

Robert Montal et al. J Hepatol. 2017 Jul.

. 2017 Jul;67(1):196-197.

doi: 10.1016/j.jhep.2017.03.004. Epub 2017 Mar 16.

¹ Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain.
² Department of Interventional Radiology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, USA.
³ Liver Cancer Translational Research Laboratory, BCLC Group, IDIBAPS, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain; Liver Cancer Program, Division of Liver Diseases, Ichan School of Medicine at Mount Sinai, New York, NY, USA; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain. Electronic address: jmllovet@clinic.cat.

No abstract available

Comment on

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC.
Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, Assenat E, Kang YK, Lim HY, Walters I, Llovet JM. Lencioni R, et al. J Hepatol. 2017 Jun;66(6):1166-1172. doi: 10.1016/j.jhep.2017.01.012. Epub 2017 Jan 26. J Hepatol. 2017. PMID: 28131794 Clinical Trial.
mRECIST for systemic therapies: More evidence is required before recommendations can be made.
Edeline J, Palmer D, Blanc JF, Campillo-Gimenez B, Merle P, Meyer T. Edeline J, et al. J Hepatol. 2017 Jul;67(1):195. doi: 10.1016/j.jhep.2017.02.033. Epub 2017 Mar 16. J Hepatol. 2017. PMID: 28315710 No abstract available.